{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107277","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.070990+00:00","generated_at":"2026-05-17T14:47:37.863002+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ALX Oncology Q2 net loss $25.9M; cash runway into Q1 2027; CD47 biomarker data highlights evorpacept potential","bullets":["GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.","Cash, equivalents & investments $83.5M; runway extended into Q1 2027 after pausing ASPEN-CRC trial.","ASPEN-06 analysis: CD47-high HER2+ gastric cancer patients had 65% ORR with evorpacept + TRP vs 26% TRP alone; full data Q4 2025.","ASPEN-Breast amended to single-arm biomarker-driven study; interim data expected Q3 2026.","ALX2004 Phase 1 first patient dosing in August 2025; initial safety data 1H2026. Allison Dillon appointed COO; Daniel Curran appointed to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107277","json":"https://secwatch.observer/filing/0000950170-25-107277.json","markdown":"https://secwatch.observer/filing/0000950170-25-107277.md","text":"https://secwatch.observer/filing/0000950170-25-107277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/0000950170-25-107277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/alxo-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:47:37.863002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}